Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst
D E
DE
University of California, Rheumatology Division, 1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA. defurst@mednet.ucla.edu.
Breedveld
F C
FC
Kalden
J R
JR
Smolen
J S
JS
Burmester
G R
GR
Bijlsma
J W J
JW
Dougados
M
M
Emery
P
P
Keystone
E C
EC
Klareskog
L
L
Mease
P J
PJ
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012795:Sialoglycoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D007155:Immunologic Factors; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha